263 related articles for article (PubMed ID: 18424763)
1. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
[TBL] [Abstract][Full Text] [Related]
2. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
3. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
4. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
Du J; Lopez-Verges S; Pitcher BN; Johnson J; Jung SH; Zhou L; Hsu K; Czuczman MS; Cheson B; Kaplan L; Lanier LL; Venstrom JM
Cancer Immunol Res; 2014 Sep; 2(9):878-89. PubMed ID: 24958280
[TBL] [Abstract][Full Text] [Related]
5. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
6. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
[TBL] [Abstract][Full Text] [Related]
7. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
10. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
11. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
13. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
Wang SY; Veeramani S; Racila E; Cagley J; Fritzinger DC; Vogel CW; St John W; Weiner GJ
Blood; 2009 Dec; 114(26):5322-30. PubMed ID: 19805620
[TBL] [Abstract][Full Text] [Related]
14. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ
Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151
[TBL] [Abstract][Full Text] [Related]
15. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
[TBL] [Abstract][Full Text] [Related]
16. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
17. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
18. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
[TBL] [Abstract][Full Text] [Related]
19. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
Enqvist M; Jacobs B; Junlén HR; Schaffer M; Melén CM; Friberg D; Wahlin BE; Malmberg KJ
Front Immunol; 2019; 10():2085. PubMed ID: 31572357
[TBL] [Abstract][Full Text] [Related]
20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
